You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Selected published results of SRS (2000–2015) for the treatment of GH-secreting pituitary adenomas

From: Target delineation and optimal radiosurgical dose for pituitary tumors

Authors Patients Type Dose Follow-up Tumor Biochemical Late toxicity (%)
of SRS (Gy) (months) control (%) remission (%) visual hypopituitarism
Zhang et al., 2000 [84] 68 GK 31a 34 100 40 NA NA
Izawa et al., 2000 [85] 29 GK 22.5a 26.4 93 41 0 0
Attanasio et al., 2003 [86] 30 GK 20a 46 100 23 0 6.3
Jane et al., 2003 [87] 64 GK 15a > 18 100 36 0 28
Castinetti et al., 2005 [88] 82 GK 28.5a 49.5 100 17 1.2 16
Gutt et al., 2005 [89] 44 GK 23a 23 100 48 0 NA
Kobayashi et al., 2005 [90] 67 GK 18.9a 63.3 100 17 11.1 14.6
Jezkova et al., 2006 [91] 96 GK 35a 53.7 100 50 (44 at 5 years) 0 27.1
Voges et al., 2006 [66] 64 LINAC 16.5 54.3 97 37.5 (33 at 5 years) 1,4 12.3 (18 at 5 years)
Petit et al., 2007 [92] 22 Protons 20 75 95 59 0 38
Pollock et al., 2007 [93] 46 GK 20a 63 100 50 (60 at 5 years) 2.2 36
Roberts et al., 2007 [82] 9 CK 18–24a 25.4 100 44.4 0 33
Vik-Mo et al., 2007 [94] 61 GK 26.5a 66 100 38 (58 at 5 years) 0 23
Jagannathan et al., 2008 [95] 95 GK 22a 57 98 53 4.2 34
Losa et al., 2008 [96] 83 GK 21.5a 69 97.6 60 (52 at 5 years) 0 8.5 (11.8 at 5 years)
Ronchi et al., 2009 [97] 35 GK 20a 114 100 82 (46 at 10 years) 0 50
Wan et al., 2009 [98] 103 GK 21.4a 67.3 95.1 36.9 NA 1.7
Hayashi et al., 2010 [70] 25 GK 25a 36 100 40 0 0
Iwai et al., 2010 [99] 26 GK 20a 84 96 38 (17 at 5 years) 0 8
Castinetti et al., 2009 [100] 43 GK 26a 96 100 42,0 0 23
Poon et al., 2010 [101] 40 GK 29a 73.8 NA 17 0 11.4
Erdur et al., 2011 [102] 22 GK 23.8a 60 95,2 54,5 0 28.6
Sheehan et al., 2011 [36] 130 GK 24a 31 93 53 2.3 34
Sicignano et al., 2012 [37] 39 GK 25a 60 97.7 54 NA 12.3
Franzin et al., 2012 [103] 103 GK 22.5a 71 97,3 60.7 (57 at 5 years) 0 7.8
Liu et al., 2012 [104] 40 GK 21a 72 97,5 47,5 0 40
Zeiler et al., 2013 [105] 21 GK 14.2a 33 100 30 3.9 13.2
Yan et al., 2013 [106] 22 LINAC 23 98 95 68.2 0 22.7
Wilson et al., 2013 [107] 86 LINAC 20 66 96 18.6 1,2 19.8
Lee et al., 2014 [108] 136 GK 25a 61.5 98.5 65.4 (73.4 at 6 years) 3.7 31.6
Wattson et al., 2014 [109] 50 Protons 20 51.5 100 48 (49 at 5 years) 0 57 (62 at 5 years)
Bostrom et al., 2015 [110] 21 LINAC 20 96 97.1 23 5 46.4
  1. SRS stereotactic radiosurgery, GK Gamma Knife, LINAC Linear Accelerator, CK CyberKnife, NA not assessed
  2. amarginal dose; ^1–3 fractions